Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: Influences of variance in pharmacokinetics and treatment regimens

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 2, 2010, Pages 269-275

  Collins, P W ^a   Bjorkman S ^b   Fischer, K ^c   Blanchette, V ^d   Oh, M ^e   Schroth, P ^e   Fritsch, S ^f   Casey, K ^e   Spotts, G ^e   Ewenstein, B M ^e  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e BAXTER HEALTHCARE CORPORATION   (United States)

^f BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

FVIII; Hemophilia A; Pharmacokinetics; Prophylaxis

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BLEEDING; CHILD; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INFUSION; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SIMULATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COAGULANTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FACTOR VIII; HALF-LIFE; HEMARTHROSIS; HEMOPHILIA A; HUMANS; INFANT; INFUSIONS, PARENTERAL; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74749088081     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03703.x     Document Type: Article

References (21)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia. N Engl J Med 2007, 357:535-44.
2. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding) [document on the Internet]. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007, Approved by the Medical and Scientific Advisory Council (MASAC) on November 3, 2007, and adopted by the NHF Board of Directors on November 4, 2007, ; Accessed 4 December 2009
3. Hay CR. Prophylaxis in adults with haemophilia. Haemophilia 2007, 13(Suppl. 2):10-5.
4. Ahlberg A. Haemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand 1965, 77(Suppl):5-99.
5. den Uijl IE, Fischer K, van der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009, 15:83-90.
6. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992, 232:25-32.
7. Ahnström J, Berntorp E, Lindvall K, Björkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004, 10:689-97.
8. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003, 9(Suppl. 1):101-8.
9. Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009, 7:413-20.
10. Carlsson M, Berntorp E, Björkman S, Lindvall K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur J Haematol 1993, 51:247-52.
11. Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM. rAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004, 10:428-37.
12. Blanchette VS, Shapiro AD, Liesner RJ, Hernandez NF, Warrier I, Schroth PC, Spotts G, Ewenstein BM. rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008, 6:1319-26.
13. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range of 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009, 65:989-98.
14. Carlsson M, Berntorp E, Björkman S, Lethagen A, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997, 3:96-101.
15. Fischer K, Astermark J, van der Bom JG, Ljung RCR, Berntorp E, Grobbee DE, van den Berg HM. Prophylactic treatment for severe haemophilia: comparison of an intermediate dose regimen to a high dose regimen. Haemophilia 2002, 8:753-60.
16. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001, 7:133-9.
17. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007, 13:2-8.
18. Collins PW, Blanchette V, Fischer K, Astermark J, Schroth P, Fritsch S, Ewenstein BM. Clinical implications of pharmacokinetic variables in the management of patients with severe hemophilia A. Blood 2006, 108:1041a.
19. Van Dijk K, van der Bom JG, Lenting P, de Groot PG, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, van den Berg HM. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005, 90:494-8.
20. Messori A, Longo G, Morfini M, Cinotti S, Filimberti E, Giustinarini G, Rossi Ferrini P. Multivariate analysis of factors governing the pharmacokinetics of exogenous Factor VIII. Eur J Clin Pharmacol 1988, 35:663-8.
21. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic versus on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe haemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010, 8:83-9.